Amgen Gives up on Its Once-Prized Eczema Drug

Why It Matters

The withdrawal removes a potential revenue stream for Amgen and highlights the difficulty of displacing entrenched biologics in eczema treatment, while giving Kyowa Kirin an opportunity to commercialize the asset independently.

Key Takeaways

• Amgen ends rocatinlimab partnership, returns rights to Kyowa Kirin
• Phase 3 showed efficacy but no advantage over Dupixent
• Fever occurred in 12.5% of patients, chills in 6%
• Side‑effect profile raises commercial and dosing concerns
• Kyowa Kirin will seek FDA, then Japan approval

Pulse Analysis

The atopic dermatitis market has been dominated for years by biologics such as Regeneron’s Dupixent, which commands billions in annual sales. Amgen’s entry with rocatinlimab, an OX40 inhibitor, promised a novel mechanism that could broaden therapeutic options beyond interleukin‑4/13 blockade. After licensing the molecule from Kyowa Kirin in 2021 for an upfront $400 million and potential $850 million milestones, the company invested heavily in late‑stage development, reflecting the high stakes of capturing market share in a fast‑growing segment projected to exceed $10 billion by 2030.

Phase 3 data published in The Lancet confirmed that rocatinlimab reduced lesion count and achieved clear‑or‑near‑clear skin, yet the efficacy gap with Dupixent proved marginal. More concerning, one in eight participants experienced fever and 6 % reported chills, side‑effects that could limit dosing intensity and patient adherence. Analysts such as Matt Phipps and David Risinger argued that these safety signals, combined with a modest sales forecast of $800 million by 2032, made the asset unattractive for Amgen’s portfolio, prompting its strategic exit.

Kyowa Kirin now assumes full responsibility for rocatinlimab, intending to file with the U.S. FDA followed by Japan’s regulator. If approved, the drug could still capture niche segments seeking alternative OX40‑targeted therapy, especially as competitors like ImageneBio explore safer variants. The episode illustrates a broader trend where large pharma firms reassess high‑cost collaborations when clinical differentiation is unclear, while smaller innovators retain the upside of niche biologics. Investors will watch Kyowa Kirin’s regulatory progress closely, as success could validate OX40 as a viable target beyond eczema.